Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Sponsor: Geisinger Clinic
Terminated
PI Law left Geisinger-study terminated prematurely - 4 patients enrolled
Other terminated trials from Geisinger Clinic
Other Head and Neck Cancer trials with similar outcome
This PHASE2 trial investigates Head and Neck Cancer and is currently terminated or withdrawn. Geisinger Clinic leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Geisinger Clinic
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .